Abstract: Murine reconstitution assays were used to investigate the effects of recombinant human interleukin-7 (rhIL-7) on myeloid and lymphoid precursors and on bone marrow engraftment. Reconstitution with bone marrow from rhIL-7-treated mice results in a 3.4-fold decrease in total colony-forming unit-spleen (CFU-S) ac tivity (day 9) and an 18.1-and 11.9-fold decrease in its ability to generate thymocytes and splenic B lineage cells, respectively. In contrast, after reconstitution with splenocytes from rhIL-7-treated mice, CFU-S activity increased 23.6-fold (day 9) and the thymocyte and splenic B lineage 
INTRODUCTION

«
The differentiation of cells of the various hemopoietic lineages involves a complex and as yet incompletely un derstood series of events. In recent years there have been advances in isolating and expressing cytokines known to be involved in hematopoiesis. Granulocyte-macrophage-colony-stimulating factor (GSF), interleukin-3 (IL-3), granulocyte-CSF, CSF-1, and IL-6 have been shown to be directly stimulatory to myeloid progenitor cells [1, 2] . In contrast, the factors that regulate lymphopoiesis at the progenitor cell level are largely unknown, despite a large body of evidence showing significant effects of various ILs on mature T cells and B cells.
The development of a long-term B lineage culture sys tem allowed the demonstration of sustained lymphopoi esis in vitro [3, 4] , whereby populations of pro-B and pre-B cells developed over a period of several months. By using this technique IL-7 was originally described as a bone marrow stromal cell-derived factor that could sup port the proliferation of B cell precursors from WhidockWitte bone marrow cultures [5] , thus demonstrating its growth/regulatory function in lymphopoiesis. Murine and human IL-7 cDNA have both been cloned, se quenced, and expressed [6, 7] and there is 60% homology at the amino acid level. Northern blot analysis of various murine and human tissues showed that the IL-7 gene is transcribed not only in the bone marrow, but also in the spleen and the thymus [6] . IL-7 was initially shown to be a B cell lineage growth factor with preferential stimulating effects on the prolif eration of B cell precursors [6, 8, 9 ]. Subsequently, it was found that ILr7 increased the number of CD3+ cells in bone marrow cultures [10] and also supported the growth of thymocytes [11] [12] [13] , in particular the CD4CD8", CD4+CD8" , and CD4'CD8+ subsets [14] . IL-7 also was shown to act as a co-stimulator for peripheral T lympho cytes, in concert with mitogen or antigen in vitro [15, 16] . In vitro, IL-7 has been shown to enhance CSF-induced proliferation of myeloid colony formation [17] .
The in vivo effects of IL-7 administration using murine systems also have been examined. Normal mice treated with recombinant murine IL-7 (rmIL-7) have increased lymphocyte numbers [18] and cyclophosphamide-treated mice were able to reconstitute the lymphocyte compart ment more rapidly with rmIL-7 treatment [19] . Further-more, administration of recombinant human IL-7 (rhlL-7) to sublethally irradiated mice resulted in accelerated repopulation of T and B lymphocytes and some immature myeloid lineage cells [20] , O u r laboratory has previously demonstrated that administration of rhIL-7 to mice in duced exportation of single lineage colony-forming unitsculture (CFU-c) and m ultilin e ag e CFU-granulocyte, erythroid, monocyte, and megakaryocyte (CFU-GEMM) colony-generating myeloid progenitors from the bone marrow to the spleen that resulted in a 90% decrease in bone marrow myeloid progenitors and a Fivefold increase in the spleen [21, 22] . We also have shown that the ad ministration of rhIL-7 resulted in a three-to fivefold inn crease in leukocytes in spleen and lymph nodes due to an increase in all major mature leukocyte subsets (B, T, and natural killer cells and macrophages) with a dispropor tionate increase in pre-B cells and C D 8+ T cells [23] . Furthermore, T cells in rhIL-7-treated mice had enhanced and accelerated abilities to respond to various stimuli [23] .
In this study we examined the effects of rhIL-7 admini stration on early myeloid and lymphoid precursors by using in vivo reconstitution assays. O u r data demonstrate that administration of rhIL-7 to mice results in a relocali zation o f the earliest (CFU-spleen [CFU-S] generating) myeloid progenitors and of lym phoid precursors from the bone marrow to the spleen. These data also demon strate an increase in pre-pro-B cells and pro-B cells and an increase in CD2+ and CD2' B cell precursors after rhIL-7 treatm ent. In a d d itio n , ad m in istratio n o f rhIL-7 to lethally irradiated mice after bone marrow transfer was able to accelerate bone marrow engraftment by up to 2-4 weeks. Thus, these data demonstrate that IL-7 has pro found effects on both myeloid and lymphoid precursors and suggest that IL-7 may have a valuable role in acceler ating bone marrow engraftment in transplant patients.
MATERIALS AND METHODS
Mice
Six-to 10-week-old female C57BL/6 (Ly 5,2) or C57BL/6-Ly 5,1 congenie mice were obtained from the Animal Production Area o f the National Cancer Institute-Frederick Cancer Research and Development Center (Frederick, MD) and were maintained under specific pathogenfree conditions.
Cytokine treatment
Recombinant human IL-7, generously supplied by Sterling Winthrop, Inc. (Collegeville, PA), had a specific biological activity of 2-5 x 107 U /m g, as measured by the proliferation of a murine pre-B cell line [7] ; the endotoxin levels were <2 endotoxin U /m g of rhIL-7. Mice were injected intrap e rito ne ally twice daily with Hanks' balanced salt solution (HBSS) containing 0.1% normal mouse serum (NMS) as a vehicle con trol or with 5 or 10 )Xg/injection of rhIL-7 in HBSS and 0.1% NMS at 0.5 ml/injection. This regimen was based on observations from our previous studies [21, 23] .
Cell suspension preparation
Bone marrow cells, splenocytes, and thymocytes were prepared as pre viously described [21, 23] . Erythrocytes in the bone marrow and splenocyte suspensions were rapidly lysed (5 s) with distilled water. After a final wash with HBSS, the cells were either injected intravenously into irradi ated recipients or labeled with antibodies for flow cytometric analysis (FCA).
CFU-S assay
The CFU-S assay was performed as described by Till and McCulloch [24] , Briefly, 6-week-old recipient mice were lethally irradiated (900 rads) by using a M ARK 1 Irradiator affixed with a 302 attenuator (J.
Reconstitution assay
Recipient mice were sublethally (750 rads) or lethally (900 rads) irradi ated 3-4 h before reconstitution. Recipients were injected intravenously with varying numbers of donor-origin bone marrow cells or splenocytes. At various times after reconstitution the recipients were euthanized and their thymi and spleens were removed for further analysis.
Immunofluorescence labeling and FCA Three mice per group were used for each time point. Single cell suspen sions were labeled with antibody and FCA was performed as previously described [21] The mAb RB6-8C5 detects the RB6-8C5 myeloid differentiation antigen, which is expressed on all granulocytes in increasing amounts as the cells mature. It also may be transiently expressed on cells undergoing macro phage differentiation [26] .
Donor-origin splenic T cells were detected in two-color analysis by using the anti-CD 3 mAb 500A2 (hamster IgG; Ref. 27 ) developed with a FITOconjugated, affinity-purified goat anti-hamster IgG (heavy and light chain specific and mouse serum absorbed) antibody (Caltag Labo ratories) combined with the anti-Ly 5.1 mAb developed as indicated above. Donor-origin splenic B lineage cells (B220+ ) and mature B cells (surface Ig | ¿+) were detected in three-color analysis by using FITC-conjugated, affinity-purified goat anti-mouse IgM (|x heavy chain specific) antibody (FisherBiotech; Fisher Scientific, Orangeburg, NY) combined with phycoerythrin-conjugated anti-B220 mAb (rat IgG2a, clone RA3-6B2; PharMingen) and anti-Ly 5.1 mAb conjugated with biotin in our laboratory and developed with streptavidin-RED613. Two sets of antibod ies were used to examine immature B lineage cells. The first combina tion included FITC-conjugated anti-CD43 mAb (rat IgG2a, clone S7; originally produced by Gulley et al. [28] and conjugated by Randy Fischer, Biological Response Modifiers Program, National Cancer Insti tute, Frederick, MD) combined with phycoerythrin-conjugated anii-B220 mAb and the second combination included FITC-conjugated anti-CD2 mAb (rat IgG2b, clone RM2-5; PharMingen) combined with phyco erythrin-conjugated anti-B220 mAb and bio tin-conjugated, affinity-puri fied goat anti-mouse IgM (ji heavy chain specific) antibody (Vector Laboratories, Inc., Burlingame, CA) developed with streptavidin-REDfi70 (GIBCO-BRL). All antibodies used were titered to determine optimal working dilutions and iso type-matched controls were used to determine the amount o f nonspecific binding. All polyclonal antibodies were pre tested and found to be highly specific with no detectable cross-reactivi ties to Igs of other species, isotypes, or subclasses.
Statistical analysis
Results from representative experiments are expressed as the mean ± sd. The significance of alterations in the numbers of leukocytes obtained from various groups was determined by Student's ¿-test. Donor C57BL/6-Ly 5.1 mice (10-55/group) were injected intraperitoneally with HBSS and 0.1% NMS or 10 (ig o f rhIL-7, respectively, twice a day for 7 days. After cessation of treatment donor bone marrow cells or splenocytes were injected intravenously into five lethally (900 rads) irradiated C57BL/6 (Ly 5.2) recipients per group. On days 9 or 12 after transfer the spleens were removed from the recipients and the number of CFU-S were enumerated. Lethally, irradiated recipient controls that were injected only with HBSS had no CFU-S on days 9 or 12. Data represent the mean ± SD.
aResults indicate the number of cells from a pool of mice divided by the number of mice. These data were calculated by multiplying the number of CFU-S per recipient spleen by the total mean cellularity of the donor organ (column 2) and dividing by the number of donor cells injected.
c Signifie an dy different from HBSS-treated controls (P<001).
in the spleens by exportation from the bone marrow to the spleen [21, 22] . To investigate the effect of rhIL-7 on even more immature erythro/myeloid progenitor cells, the in vivo CFU-S assay was performed. Donor C57BL/6-Ly 5.1 mice were injected intraperitoneally with HBSS and 0.1% NMS or 10 jig of rhIL-7 twice a day for 7 days. O n the following day 2 X IO5 bone marrow cells or 5 X 105 splenocytes from these mice were injected intrave nously into lethally irradiated (900 rads) C57BL/6 (Ly 5.2)-recipient mice. On days 9 or 12 after transfer the spleens were removed from the recipient mice and CFU-S were enumerated. The results in Table 1 demonstrate that the number of CFU-S generated after transfer of bone marrow cells from rhIL-7-treated mice decreased by 7.5-fold (day 9) when compared with the numbers gener ated after injection of HBSS and 0.1 % NMS-treated con trol cells. However, the number of CFU-S generated after transfer o f splenocytes from rhIL-7-treated mice in creased by 4.3-fold (day 9) or 3.0-fold (day 12) when com pared with the numbers generated after the injection of HBSS and 0.1% NMS-treated control cells. Furthermore, because o f the ability of rhIL-7 treatment to significantly increase, splenic cellularity [23] there was a 23.6-fold (day 9) or 15.5-fold (day 12) increase in the CFU-S-generating capacity of splenocytes from rhIL-7-treated mice on a per organ basis (Table 1) . Because rhIL-7 treatment does not decrease bone marrow cellularity [2 1], there was still a 3.4-fold (day 9) decrease in CFU-S-generating capacity in bone marrow on a per organ basis from rhIL-7-treated mice.
Lymphocyte regeneration after transfer of bone marrow cells or splenocytes from rhlL-7-treated mice into irradiated recipients
To determine the effects of rhIL-7 on lymphoid progeni tors in the bone marrow and spleen, sublethally (750 rads) irradiated C57BL/6 (Ly 5.2) mice were injected intravenously with 5 x IO6 bone marrow cells or 40 X 106 splenocytes from C57BL/6-Ly 5.1 mice that had been treated intraperitoneally with HBSS and 0.1% NMS or rhILr7 (10 jxg/injection) twice a day for 7 days. O n day 15 after transfer the thymi and spleens were removed from the recipients. The generation of donor-origin cells in the thymus and donor-origin B lineage cells in the spleen was determined by FCA. The results in Table 2 demonstrate that the bone marrow from rhIL-7-treated mice had a 21-and 13.7-fold decrease in the ability to reconstitute the. donor-origin thymocytes and B220+ splenocytes, respec tively, early after transfer when compared with cells from vehicle control-treated mice. The fold decrease in the relative number of precursors on a per organ basis in bone marrow from rhIL-7-treated mice compared with HBSS and 0.1% NMS-treated mice was similar (18.1-fold for thymocytes and 11.9-fold for B220+ splenocytes). In contrast, the reconstituting activity of splenocytes from rhIL-7-treated mice was not significandy different from splenocytes obtained from untreated mice in their ability to reconstitute the thymus o f irradiated mice compared with controls.
A decrease was observed in the ability of splenocytes from rhIL-7-treated mice to generate donor-origin B220* cells (2.4-fold) in the spleens o f recipient mice compared with controls (Table 2) . However, when the reconstituting ability of splenocytes from rhIL-7-treated mice was calcu lated on a per organ basis, as shown in Table 2 , there was actually an increase in the ability o f these splenocytes to reconstitute the thymus (4.0-fold) and B220+ splenocytes (3,2-fold) when compared with the reconstituting ability of splenocytes from HBSS and 0.1 % NMS-treated control mice.
rhIL-7 administration results in increased cell numbers at several stages of B ceil differentiation
As previously reported, rhIL-7 administration expands pre-B cell and mature B cell numbers, up-regulates BP-1, and increases the numbers o f cytoplasmic (i-chain-positive cells and the frequency o f colony-forming cell-pre-B cells [18, 23] . To extend these observations, bone marrow cells and splenocytes from HBSS-or rhIL-7-treated mice were examined to quantitate specific stages o f B cell differen tiation by using FCA. The phenotypic markers B220 and CD43 were used to identify pre-pro-B cells and pro-B cells, which have been reported to express low levels of both o f these markers [29] . The profiles in Figure 1A show the distribution o f bone marrow cells and spleno cytes from HBSS-or rhIL-7-treated mice based on B220 and CD43 expression and the box within each profile indicates the area that contains pre-pro-B cells and pro-B cells. The percentage and numbers of cells within each box are shown in Table 3 in the column labeled B220low+ Donor C57BL/6-Ly 5.1 mice (5-25/group) were treated as described in Table 1 . After treatment donor bone marrow or spleen cells were injected intravenously into sublethally (750 Tads) irradiated C56BL/6 (Ly 5.2) recipients. Fifteen days after transfer the thymi and spleens from S mice/group were assayed by using FCA to determine the number of donor-origin cells in the thymus or the number of donor-origin B220+ cells in the spleen of recipient mice. Data represent the mean ± SD.
flResults indicate the number of cells from a pool of mice divided by the number of mice. These data were calculated by multiplying the number of donor thymocytes or B220* splenocytes per recipient spleen by the total mean cellularity of the donor organ (column 2) and dividing by the number of donor cells injected.
Significantly different from HBSS-treated controls (P<,01).
Significantly different from HBSS-treated controls (P<.Q5).
Significantly different from HBSS-treated controls (Pc.OOl).
CD43low4\ Bone marrow and spleens from rhIL-7-treated mice had an approximately two-to threefold increase in the numbers of these cells compared with controls. The expression of CD2 in combination with B220 and surface Ig | i expression was also examined on the bone marrow cells and splenocytes from HBSS-or rhIL-7-treated mice. All surface Igji-positive B cells expressed CD2 in both HBSS-and rhIL-7-treated mice (data not shown). W ork by Sen et al, [30] showed that CD2 is expressed not only on mature B cells but also on pre-B (surface Ig | r , B220+ ) cells expressing cytoplasmic (¿-chain. Therefore, the expression of C D 2 on surface Ig|J.-negative cells was also quantitated. The profiles shown in Figure  IB illustrate the distribution o f B220 and CD2 on surface Ig^L-negative cells from the bone marrow and spleen of HBSS-or rhIL-7-treated mice. The corresponding per centages and numbers given in Table 3 demonstrate that less than 5% of total bone marrow cells from HBSStreated mice are surface Ig(T, B220+ , CD2* cells. However, bone marrow cells from rhIL-7-treated mice have an 11.6-fold increase in the numbers o f these cells. Spleen cells from HBSS-treated mice have virtually no cells o f this phenotype. However, 9.99% (26.53 x 106) of total spleno cytes are surface Ig^l", B220+ , CD2' after rhIL-7 administra tion.
Pre-pro-B cells and pro-B cells are contained the in the surface Ig | r , B220+ , C D 2* cells. W hen the percentage of B220low+, CD43low+ cells that contain pre-pro-B cells and pro-B cells is subtracted from the surface Igjj;, B220+ , CD2' cell percentage, 36% (13.78 x 10 6) of total bone marrow cells from rhIL-7-treated mice remain. This dem onstrates that the majority o f the cell expansion in the surface Igp;, B220+ , CD2' subset was not due to pre-pro-B cells or pro-B cell expansion but due to a disproportion ate expansion of another B lineage stage, most likely pre-B cells that do not express CD2. Similar results were obtained for splenocytes from rhIL-7 mice. After rhIL-7 administration, there was a 10.8-and 45.8-fold increase in the numbers of cells in the surface Igjr, B220+ , CD2+ B lineage cell subset in the bone marrow and spleen, respec tively, compared with HBSS controls. rhIL-7 accelerates lymphoid regeneration in lethally irradiated mice given a bone marrow transfer from normal mice C57BL/6 (Ly 5.2) mice were lethally (900 rads) irradiated and injected with 10 x IO6 bone marrow cells from un treated C57BL/6-Ly 5.1 congenic mice. After transfer recipient mice were injected intraperitoneally with HBSS and 0.1% NMS or 5 |Ll g of rhIL-7 twice a day throughout the course o f the experiment. At varying times after trans fer, recipient mice were examined by FCA to determine the am ount of donor-origin myeloid reconstitution in the spleen. Administration of rhIL-7 resulted in a minor en hancem ent in myeloid reconstitution compared with bone marrow recipients treated with HBSS and 0.1% NMS (Fig. 2) .
In a similar experiment, FCA was used to determine the total num ber o f donor-origin cells generated and the am ount o f donor-origin T cell and B cell reconstitution in the spleen. The generation of donor-origin splenocytes was accelerated in recipient mice that received rhIL7 treatment (Fig, 3) . Recipient mice treated with HBSS and 0.1% NMS took up to 4 weeks longer to reach equivalent levels of reconstitution. Donor-origin subset analysis in the recipients' spleens was performed using FCA. Exami nation of donor-origin B cell numbers in Figure 4 and donor-origin T cell numbers in Figure 5 demonstrate that treatment o f bone marrow recipient mice with rhIL-7 greatly enhanced the speed of reconstitution o f both the B cell and T cell compartments by up to 4 and 2 weeks, respectively, compared with bone marrow recipients treated .with the vehicle control. CD4/CD8 analysis indi cated that both the helper CD4+ T cells as well as the cytotoxic CD8+ T cells underwent this expansion (Table  4) . However, administration of rhIL-7 appeared to prefer entially expand the CD8+ T cells, which we have pre viously described when normal mice are treated with rhIL-7 [20, 23] . 
DISCUSSION
The effects of rhIL-7 on lymphoid and myeloid progeni tors and on lymphoid and myeloid lineage repopulation were investigated by using C57BL/6 congenie mice. Re combinant human IL-7 treatment markedly influenced the ability o f bone marrow and spleen cells to generate CFU-S when transferred into irradiated recipients result ing in a 3.4-fold reduction or a 23.6-fold increase in the capacity of bone marrow or spleen cells, respectively, to form day 9 CFU-S generated from precursors thought to be committed to a particular lineage [31] . Furthermore, day 12 CFU-S-generating capacity that arises from uncom mitted precursors [31] was increased 15.5-fold in spleno cytes from rhIL-7-treated mice. Although our previous data [2 1] demonstrated that localization of myeloid pro genitors capable of generating CFU-c and CFU-GEMM is affected by rhIL-7 administration, the results presented here extend these observations to show that the numbers a n d lo c a liz a tio n o f the e arlie st d e te c ta b le erythro/myeloid progenitors also are affected by in vivo rhIL-7 treatment. Because in vivo administration of rhIL-7 had pro nounced effects on various stages of myeloid progenitors, we also examined its effects on lymphoid progenitors. The results presented here are the first demonstration that rhlL-7 administration to mice also affects localization of lymphoid precursors. Specifically, on a per organ basis, bone marrow from mice treated with rhIL-7 for 7 days had an 11.9-and 18.1-fold decrease in the ability to recon stitute the B and T lineages, respectively, in irradiated recipients. However, the spleens from rhIL-7-treated mice had a three-to fourfold increase in their ability to repopu late the lymphoid lineages. These effects were reversible and dependent on the length o f rhIL-7 treatment (data not shown). Thus, in vivo adm inistration rhIL-7 signifi cantly affects the localization and numbers o f both lym phoid and myeloid precursors and, moreover, recent results from our laboratory suggest that similar effects o f rhIL-7 administration on the stem cell compartment oc cur as well [32] .
The mechanisms by which IL-7 exerts its effects are n o t clear, however, these data com bined with previously p u b lished results suggest that IL-7 may act (directly or in d i rectly) first by m o b ilizin g precursor cells to extra medullary sites. This hypothesis is supported by the sub stantial IL-7-induced reduction in precursor cells in the bone marrow that coincide with an increase in those cells in the spleen. The second com ponent o f the IL-7-induced effect is probably due to the induction o f differentiation and expansion of the number o f precursors that result in increased numbers of mature lym phoid and myeloid lin e age cells. Additional experiments are in progress to ad dress these issues. The FCA profiles illustrated in Figure 1 were analyzed to determine the percentage of cells bearing indicated phenotypic markers. The data presented here show the percentages and also the calculated cell numbers for each subset. The percentages listed indicate the percentage of a particular subset based on the total splenocyte or bone marrow cell population.
In addition to documenting the effects of rhIL-7 ad ministration on the ability o f progenitors to repopulate cells of the B lineage, we also examined the effect of rhIL-7 on specific stages of B cell differentiation, as de fined by phenotypic markers using FCA. The results pre sented here demonstrate that pre-pro-B cells and pro-B cells expand in number by two-to threefold in the spleen and bone marrow of rhIL-7-treated mice. This supports the work of Hardy et al. [29] , demonstrating in vitro that In comparing the reconstitution data with the FCA data, it is quite clear that although rhIL-7 administration expands B lineage stages from the pre-pro-B cells and onward in the bone marrow, the precursor responsible for B cell reconstitution is not increasing in the bone marrow (Table 2) . There are several possible explanations to account for this. One possibility is that precursors responsible for reconstitution have migrated from the bone marrow to the spleen and this has been addressed above. A second possibility is that the cells are rendered inactive by IL-7 either by functional inhibition or death. This is unlikely based on our results demonstrating that rhIL-7 accelerates B cell reconstitution after normal bone marrow transplantation. A third possibility is that the cells Donor-origin splenic T cells shown in Figure 5 were further analyzed by FCA to determine the number of cells contained in the CD4+ and CD8+ subsets. Data represent the mean ± SD of 3 mice/group. "Significantly different from HBSS-treated controls (Pc.Ol).
Significantly different from HBSS-treated controls (P< .001).
Significantly different from HBSS-treated controls (P<.05), that are capable of repopulating the B cell lineage have been used to support the dramatic expansion of pre-pro-B cells to mature B cells and are thus depleted. The recon stitution data support this possibility in that these precur sors appear to be essential for the B cell expansion in bone marrow-transplanted mice. Because IL-7 generated a leukocytosis in normal mice [18, 23] and accelerated lymphocyte repopulation in cy clophosphamide-treated mice [19] and sublethally irradi ated mice [20] , its potential application in accelerating myeloid and /o r lymphoid reconstitution after bone mar row transplantation was studied in the C57BL/6 Ly 5 congenic mouse model. Lethally irradiated mice that had received norm al donor-origin bone marrow cells and were treated with rhIL-7 had somewhat enhanced myeloid reconstitution in mice treated with rhIL-7. How ever, lymphoid reconstitution was both accelerated and enhanced for both donor-origin T cells and B ceils. By 13 days after bone marrow transfer there was a 3.4-fold in crease in B cell reconstitution in recipients treated with rhIL-7 compared with those that had received only HBSS and 0.1% NMS. There was also a fourfold increase in the number of T cells generated in recipient mice treated with rhIL-7 compared with controls until at least the 3rd to 4th week after transfer when reconstitution of T cells in control mice began to approach that o f the rhlL-7-treated group. Furthermore, there was no observeable toxic effect of long-term (6 weeks) rhIL-7 treatment in < 0
Number of Days After Bone Marrow Cell Transfer these experiments, unlike the study of Fraser et al. [33] in which 23% of lethally irradiated recipient mice that had received bone marrow infected with a retrovirus express ing the m.IL-7 gene were m oribund within 4-16 weeks after transplantation. These data illustrate that rhIL-7 ad ministration is able to accelerate bone marrow engraft ment after transplantation.
The results presented here demonstrate that IL-7 has potent effects on lym phoid and myeloid mobilization and accelerates bone marrow engraftment in lethally irradi ated recipients. Thus, IL-7 administration may be impor tant in the enhancement and acceleration o f lymphoid and myeloid regeneration in myeloablated cancer pa tients who subsequently receive bone marrow transplants.
